197 related articles for article (PubMed ID: 1923532)
21. p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas.
Weyrer K; Feichtinger H; Haun M; Weiss G; Ofner D; Weger AR; Umlauft F; Grünewald K
Lab Invest; 1996 Jan; 74(1):279-89. PubMed ID: 8569192
[TBL] [Abstract][Full Text] [Related]
22. Mutations in the p53 gene in myelodysplastic syndromes.
Jonveaux P; Fenaux P; Quiquandon I; Pignon JM; Laï JL; Loucheux-Lefebvre MH; Goossens M; Bauters F; Berger R
Oncogene; 1991 Dec; 6(12):2243-7. PubMed ID: 1766671
[TBL] [Abstract][Full Text] [Related]
23. Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract.
Chung KY; Mukhopadhyay T; Kim J; Casson A; Ro JY; Goepfert H; Hong WK; Roth JA
Cancer Res; 1993 Apr; 53(7):1676-83. PubMed ID: 8453641
[TBL] [Abstract][Full Text] [Related]
24. P53 mutations in tissue from Danish ovarian cancer patients: from the Danish "MALOVA" ovarian cancer study.
Høgdall EV; Kjaer SK; Blaakaer J; Christensen L; Glud E; Vuust J; Høgdall CK
Gynecol Oncol; 2006 Jan; 100(1):76-82. PubMed ID: 16183105
[TBL] [Abstract][Full Text] [Related]
25. p53 mutation is infrequent in clear cell carcinoma of the ovary.
Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
[TBL] [Abstract][Full Text] [Related]
26. p53 mutations in human lung tumors.
Miller CW; Simon K; Aslo A; Kok K; Yokota J; Buys CH; Terada M; Koeffler HP
Cancer Res; 1992 Apr; 52(7):1695-8. PubMed ID: 1312896
[TBL] [Abstract][Full Text] [Related]
27. Molecular diagnosis of p53 mutations in gastric carcinoma by touch preparation.
Ricevuto E; Ficorella C; Fusco C; Cannita K; Tessitore A; Toniato E; Gabriele A; Frati L; Marchetti P; Gulino A; Martinotti S
Am J Pathol; 1996 Feb; 148(2):405-13. PubMed ID: 8579104
[TBL] [Abstract][Full Text] [Related]
28. Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas.
Komuro H; Hayashi Y; Kawamura M; Hayashi K; Kaneko Y; Kamoshita S; Hanada R; Yamamoto K; Hongo T; Yamada M
Cancer Res; 1993 Nov; 53(21):5284-8. PubMed ID: 8221663
[TBL] [Abstract][Full Text] [Related]
29. p53 Mutations in human hepatocellular carcinomas from Germany.
Kress S; Jahn UR; Buchmann A; Bannasch P; Schwarz M
Cancer Res; 1992 Jun; 52(11):3220-3. PubMed ID: 1317262
[TBL] [Abstract][Full Text] [Related]
30. Mutations of the p53 gene are not detectable in human testicular tumors.
Fleischhacker M; Strohmeyer T; Imai Y; Slamon DJ; Koeffler HP
Mod Pathol; 1994 May; 7(4):435-9. PubMed ID: 8066072
[TBL] [Abstract][Full Text] [Related]
31. Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations.
Cornelis RS; van Vliet M; Vos CB; Cleton-Jansen AM; van de Vijver MJ; Peterse JL; Khan PM; Børresen AL; Cornelisse CJ; Devilee P
Cancer Res; 1994 Aug; 54(15):4200-6. PubMed ID: 8033152
[TBL] [Abstract][Full Text] [Related]
32. Application of the p53 gene mutation pattern for differential diagnosis of primary versus metastatic lung carcinomas.
Noguchi M; Maezawa N; Nakanishi Y; Matsuno Y; Shimosato Y; Hirohashi S
Diagn Mol Pathol; 1993 Mar; 2(1):29-35. PubMed ID: 8287223
[TBL] [Abstract][Full Text] [Related]
33. Characterization of p53 gene mutations in colorectal carcinomas from an Asian population.
Shi CY; Phang TW; Ngoi SS; Wee A; Li B; Lin Y; Lee HP; Ong CN
Anticancer Res; 1994; 14(6B):2811-6. PubMed ID: 7872723
[TBL] [Abstract][Full Text] [Related]
34. p53 mutation, allele loss on chromosome 17p, and DNA content in ovarian carcinoma.
McManus DT; Murphy M; Arthur K; Hamilton PW; Russell SE; Toner PG
J Pathol; 1996 Jun; 179(2):177-82. PubMed ID: 8758210
[TBL] [Abstract][Full Text] [Related]
35. Chromosome 17p deletions and p53 mutations in renal cell carcinoma.
Reiter RE; Anglard P; Liu S; Gnarra JR; Linehan WM
Cancer Res; 1993 Jul; 53(13):3092-7. PubMed ID: 8319216
[TBL] [Abstract][Full Text] [Related]
36. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
Righetti SC; Della Torre G; Pilotti S; Ménard S; Ottone F; Colnaghi MI; Pierotti MA; Lavarino C; Cornarotti M; Oriana S; Böhm S; Bresciani GL; Spatti G; Zunino F
Cancer Res; 1996 Feb; 56(4):689-93. PubMed ID: 8630996
[TBL] [Abstract][Full Text] [Related]
37. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
38. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
Laframboise S; Chapman W; McLaughlin J; Andrulis IL
Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
[TBL] [Abstract][Full Text] [Related]
39. Base transitions are the most frequent genetic changes at P53 in gastric cancer.
Renault B; van den Broek M; Fodde R; Wijnen J; Pellegata NS; Amadori D; Khan PM; Ranzani GN
Cancer Res; 1993 Jun; 53(11):2614-7. PubMed ID: 8495424
[TBL] [Abstract][Full Text] [Related]
40. Is it possible to diagnose malignancy from fluid in cystic ovarian tumors?
Yamada R; Maeda N; Oguri H; Adachi Y; Takeuchi T; Furihata M; Fukaya T
Eur J Obstet Gynecol Reprod Biol; 2013 Nov; 171(1):96-100. PubMed ID: 24017961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
